TNF Pharma raises $600k via private placement at 20% premium; CRO partner engaged

Q/C TECHNOLOGIES, INC.

Sold 283,019 shares at $2.12/share (120% of 30-day VWAP) to Prevail Partners, gross proceeds $600k.
Proceeds for working capital; may be used to pay Prevail InfoWorks invoices under an August 2024 services agreement.
Prevail InfoWorks engaged as CRO for upcoming Phase 2 sarcopenia/frailty study of MYMD-1 TNFα inhibitor.
Press release states company is fully funded for clinical trials for next two years.
MYMD-1 previously met primary endpoints in a small Phase 2 sarcopenia study (2023) reducing chronic inflammatory markers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.